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Background: Metastasis is the major cause of cancer-related death in patients with gastric cancer, and aberrant
expression of various microRNAs (miRNAs) is associated with cancer metastasis.
Methods: Profiling of differentially expressed miRNAs was performed in three cases of primary gastric cancer and
the corresponding metastatic lymph node tissues. Then, the five most altered miRNAs were further verified in 16
paired samples. Two of these five miRNAs were further assessed for their effects on the regulation of gastric cancer
cell growth and invasion.
Results: The miRNA profile data showed 151 upregulated miRNAs (≥ 1.5-fold) and 285 downregulated miRNAs
(≤ 0.67-fold) in the metastatic tissues compared to the primary gastric cancer tissues. Among these five miRNAs
(i.e., hsa-miR-508-5p, hsa-miR-30c, hsa-miR-337-3p, hsa-miR-483-5p, and hsa-miR-134), expression of hsa-miR-337-3p
and hsa-miR-134 was significantly downregulated in these 16 lymph node metastatic tissues compared to their
primary tumor tissues (P<0.05) and in nine gastric cancer cell lines compared to the nonmalignant GES cell line.
Furthermore, induction of hsa-miR-134 or hsa-miR-337-3p expression did not dramatically affect gastric cancer cell
proliferation, but transfection of the hsa-miR-337-3p mimic did reduce gastric cancer cell invasion capacity.
Conclusions: These findings indicate that hsa-miR-337-3p plays a role in the reduction of gastric cancer cell invasion
capacity, and further studies on the mechanism of hsa-miR-337-3p in gastric cancer metastasis are warranted.
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Gastric cancer is a significant health problem, accounting
for approximately one million new cases and more than
700,000 cancer-related deaths annually in the world [1-3].
Although the incidence of gastric cancer has substantially
decreased in most parts of the world for the past few de-
cades, partially due to consumption of more fresh fruits
and reduction of Helicobacter pylori infection in the popu-
lation [1-3], to date, a large number of patients with gastric
cancer are still diagnosed at advanced stages, which makes
curative surgery difficult. Approximately 80% of such pa-
tients will die within a short period of time due to regional
recurrence or distant metastasis [4,5]. Tumor metastasis* Correspondence: wzshahbb@163.com; qiongwu68@outlook.com
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reproduction in any medium, provided the orinvolves a complex series of steps in which tumor cells
leave their original site and spread to distant organs or tis-
sues. Metastasis is the major cause of cancer-related death,
and the underlying molecular mechanisms are not fully
understood. However, it is known that increased migration
and invasion of primary cancer cells are the primary means
by which gastric cancer cells spread to distant sites. Thus,
there is an urgent need and a great clinical interest to bet-
ter understand the molecular mechanisms responsible for
gastric cancer metastasis in order to improve the outcome
of gastric cancer patients.
To this end, our recent research on gastric cancer has
focused on microRNAs (miRNAs), which are small,
single-stranded noncoding RNA molecules of 19–23 nu-
cleotides in length that are able to post-transcriptionally
regulate target gene expression [6]. So far, several hun-
dred miRNAs have been identified in plants, animals,td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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regulate many cellular processes through binding to
3′-untranslated regions (UTRs) and other regions of
protein-coding mRNA sequences of their target mRNAs
to cause mRNA degradation or inhibit its translation [7].
Thus, altered miRNA expression plays a role in tumor de-
velopment and progression, such as tumor cell prolifera-
tion, invasion, and metastasis [8]; in addition, certain
miRNAs also can predict the prognosis of various cancers,
including gastric, breast, lung, and prostate cancers [9,10].
In gastric cancer, aberrant expression of miRNAs has been
linked to tumor metastasis; for example, plasma levels of
miR-223, miR-21, miR-218, and miR-25 have been linked
to gastric cancer metastasis [11,12]. Furthermore, elevated
miR-21 expression is associated with lymph node metasta-
sis of gastric cancer [13]. Thus, these miRNAs could be
useful as biomarkers to predict gastric cancer lymph node
metastasis. In addition, miR-625 expression is significantly
downregulated and inversely associated with lymph node
metastasis of gastric cancer [14]. Therefore, in the present
study, we first performed miRNA array analysis to profile
differentially expressed miRNAs between primary and sec-
ondary gastric cancer tissues. We found that the expres-
sion of hsa-miR-134 and hsa-miR-337-3p was significantly
less in metastatic lymph node tissues than in primary tu-
mors of gastric cancer. Next, we investigated the effects of
hsa-miR-134 or hsa-miR-337-3p on the inhibition of gas-
tric cancer cell growth and invasion. The results of this
study may be useful to find potential therapeutic agents to
inhibit gastric cancer metastasis.
Methods
Tissue samples
In this study, samples of human primary gastric cancer
and the corresponding metastatic lymph node tissues
were collected from 19 patients and stored in liquid ni-
trogen until use. The demographic data of these patients
are shown in Table 1. The institutional review board of
the First Affiliated Hospital of Bengbu Medical CollegeTable 1 List of miRNAs found to be less expressed in
metastatic lymph node tissues compared to the
corresponding primary gastric cancer tissues as
determined by miRNA microarray analysis
miRNA Relative expression level (−ΔCT, Mean ± SD)
GC LN P value by
paired T-test
hsa-miR-483-5p −1.08±3.08 −2.49±3.56 0.241
hsa-miR-508-5p −5.49±1.64 −7.48±1.96 0.069
hsa-miR-30c 4.37±3.70 2.27±5.47 0.058
hsa-miR-134 0.92±4.48 −1.50±4.19 0.022*
hsa-miR-337-3p −3.67±3.32 −6.04±2.73 0.005*
Gastric cancer (GC) vs. lymph nodes (LN); n=3; *P<0.05.approved our protocol, and the patients signed a consent
form to participate in this study.
RNA isolation and miRNA microarray profiling
Total cellular RNA was isolated from tissue specimens using
TRIzol® reagent (Invitrogen, Carlsbad, CA). Briefly, the fro-
zen tissues were homogenized by using a biopulverizer with
Mini-Bead-Beater-16 and added to TRIzol® reagent for RNA
isolation according to the manufacturer’s instructions. The
RNA purity was assessed by measuring the absorption rate
at 260 nm and at 280 nm in a NanoDropND-1000 spectro-
photometer (A260/A280 ratio of 1.8–2.1 was considered
acceptable), and the RNA integrity number (RIN) was
detected by an Agilent 2000 analyzer (RIN≥8.0).
Next, these RNA samples of human primary gastric can-
cer and the corresponding metastatic tissues were reversely
transcribed into cDNA, labeled with Hy3 and Hy5, and
used as probes for miRNA profiling using the miRCURYTM
LNA system (MicroRNA array V10.0 whole list, LC
Sciences, Houston, TX). After bioinformatics analysis
of the primary gastric cancer and metastatic tissue sam-
ples, the differentially expressed miRNAs were identified.
Quantitative reverse transcription polymerase chain
reaction (qRT-PCR)
To confirm some of these differentially expressed miRNAs,
tumor tissues were harvested and stored in RNAlater solu-
tion (Ambion, Austin, TX). Total cellular RNA was isolated
from RNAlater-fixed tumor tissues or fresh cultured cells
by using the mirVana™ miRNA isolation kit (Ambion,
Austin, TX) and reversely transcribed into cDNA with the
TaqMan® MicroRNA reverse transcription kit (Applied
Biosystems, Foster City, CA). Taqman gene expression as-
says (Applied Biosystems) were used to assess expression
levels of hsa-miR-508-5p, hsa-miR-337-3p, hsa-miR-30c,
hsa-miR-483-5p, hsa-miR-134, and U6 in tissues or
cultured cells by the 7900HT fast real-time PCR sys-
tem (Applied Biosystems, Darmstadt, Germany). Rela-
tive expression levels of each miRNA were calculated
using the ΔΔCT method after normalization with U6
levels (an internal control).
Cell lines and culture
A nonmalignant GES cell line and nine human gastric
cancer cell lines (SNU1, SNU5, AGS, HGC-27, BGC-823,
MGC-803, SGC-7901, MKN-28, and MKN-45) were ori-
ginally purchased from the Cell Bank of the Chinese
Academy of Science (Shanghai, China), stored, recovered,
and used at an early passage from cryopreservation in li-
quid nitrogen. These cells were maintained in RPMI 1640
medium containing 10% fetal bovine serum (FBS), 2 mM
L-glutamine, penicillin (100 units/mL), and streptomycin
(100 μg/mL). All cell lines were cultured in 6-well plates
in humidified air supplemented with 5% CO2 at 37°C.
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used for qRT-PCR, respectively.
Design of siRNA oligonucleotides and transfection into
tumor cells
The oligonucleotides were synthesized by GenePharma
(GenePharma, Shanghai, China) and hsa-miR-134 and
hsa-miR-337-3p mimics and inhibitors were purchased
from Ambion (Austin, TX). miRNA mimics and inhibitors,
and siRNA transfection was performed using FuGene® HD
transfection reagent (Roche, Mannheim, Germany). In
brief, cells were plated in a 24-well plate and grown to
50% confluency. Then, 1 μl of FuGene® HD transfec-
tion reagent was diluted in 50 μl of Opti-MEM® I Reduced
Serum Medium (GIBCO BRL). After that, 100 pmol of
siRNA oligomer was diluted in 50 μl of Opti-MEM® I Re-
duced Serum Medium without serum (final concentration
of oligonucleotides when added to the cells was 20 μM
according to the protocol of the manufacture and the pre-
liminary experiments). The FuGene® HD transfection
complex and the diluted oligonucleotides were mixed gen-
tly and incubated at room temperature. After incubation
for 20 min, the complexes were added to each well
containing cells and medium. The cells were incubated for
6 h at 37°C in a CO2 incubator prior to testing for
transfection.
Cell proliferation assay
A CCK-8 (Dojindo, Shanghai, China) cell proliferation
assay was used to assess cell proliferation, according to
the manufacturer’s protocol. Briefly, cells were grown
and transfected with hsa-miR-134 and hsa-miR-337-3p
mimics and inhibitors (50 nM miRNA scrambled control
or miRNA mimic or 200 nM miRNA inhibitor scram-
bled control or miRNA inhibitor) for 48 h [15], de-
tached, and cultured in triplicate in 96-well cell culture
plates. At the end of the experiments, the cells were
washed with phosphate-buffered saline (PBS), fixed in
1% glutaraldehyde, and stained with 10% CCK-8. The op-
tical density (OD) at 450 nm was directly measured with a
Bio-Rad microplate reader (Hercules, CA).
Tumor cell invasion assay
Gastric cancer cell invasion capacity was assessed by
using a two-chamber migration system. The upper com-
partment was inserted into the lower compartment of
the BD BioCoat control inserts (BD Discovery Labware,
Bedford, MA), 5 × 104 cells in 0.1 mL of serum-free
medium containing 1% bovine serum albumin (BSA)
were seeded into the upper compartment, and the lower
compartment was filled with normal culture medium
supplemented with 20% FBS. After incubation for 24 h,
cells were wiped away from the upper surface and the
cells on the lower surface, which represented the cellsthat migrated through the control insert membrane,
were fixed and stained with crystal violet (Sigma). The
number of cells that migrated completely across the fil-
ter was determined in five random fields (×400 magnifi-
cation) for each experiment. Each condition was assayed
in triplicate, and each experiment was repeated at least
three times.
Statistical analysis
All experiments were repeated at least three times on
different occasions. The results are presented as the
mean ± standard deviation (SD) for all values. A paired
Student’s t-test was used to evaluate statistically signifi-
cant differences between the parameters of the primary
tumor tissues and the metastatic tumor tissues. Analysis
of variance (ANOVA) was used for miRNA selection
from the miRNA microarray study. P<0.05 was consid-
ered statistically significant.
Results
miRNA expression profiles of gastric cancer tissues and
the corresponding metastatic lymph node tissues
In this study, we first profiled differentially expressed
miRNAs between gastric cancer and the corresponding
metastatic lymph node tissues. After profiling three cases
of paired tissue samples (the pathology of these cancer tis-
sues is listed in Additional file 1: Figure S1), we found
151 upregulated miRNAs (≥1.5-fold; Additional file 2:
Table S1) and 285 downregulated miRNAs (≤0.67-fold)
in the metastatic tissues compared to the primary gas-
tric cancer tissues (Additional file 2: Table S1). Specif-
ically, expression of hsa-miR-508-5p, hsa-miR-483-5p,
hsa-miR-134, hsa-miR-30c, and hsa-miR-337-3p was
reduced in all three metastatic cancer tissues. Thus, we
selected these five miRNAs for further confirmation
(Table 1) and found that expression of hsa-miR-337-3p
and miR-508-5p was four times greater in the primary
cancer tissues compared to the metastatic gastric can-
cer tissues, while miR-483-5p expression was 2.6 times
greater, miR-30c expression was 2.14 times greater, and
miR-134 expression was 4.9 times greater in the primary
cancer tissues compared to the metastatic gastric cancer
tissues (Table 1).
Loss of hsa-miR-337-3p and hsa-miR-134 expression in
metastatic lymph node tumors
Next, we verified these five selected miRNAs in 16 pairs
of primary and secondary gastric cancer tissues using
qRT-PCR. Our data showed differential expression of
hsa-miR-508-5p, hsa-miR-483-5p, hsa-miR-134, hsa-miR-
30c, and hsa-miR-337-3p in these 16 paired samples
(Figure 1), while expression levels of hsa-miR-337-3p

































































































Figure 1 (See legend on next page.)
Wang et al. Journal of Experimental & Clinical Cancer Research 2013, 32:76 Page 4 of 9
http://www.jeccr.com/content/32/1/76
(See figure on previous page.)
Figure 1 hsa-miR-508-5p, hsa-miR-483-5p, hsa-miR-134, hsa-miR-30c, and hsa-miR-337-3p in primary gastric cancer and the
corresponding metastatic lymph node tissue. Differential expression of hsa-miR-508-5p (A), hsa-miR-483-5p (B), hsa-miR-134 (C), hsa-miR-30c
(D), and hsa-miR-337-3p (E) in 16 paired samples of primary gastric cancer (GC) and the corresponding metastatic lymph node tissues (LN) as
determined by qRT-PCR. The values shows the fold change of the expression level of LN versus GC (n=3).
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tissues (Table 1).
Expression of hsa-miR-134 and hsa-miR-337-3p in
nonmalignant gastric cells and gastric cancer cells
To determine the potential role of hsa-miR-134 and hsa-
miR-337-3p in gastric cancer, we assessed their expressionA
B
Figure 2 Expression of hsa-miR-134 and hsa-miR-337-3p in the nonm
hsa-miR-134; B, hsa-miR-337-3p.in a nonmalignant gastric cell line (GES) and nine gastric
cancer cell lines (SNU-1, SNU-5, AGS, HGC-27, BGC-
823, MGC-803, SGC-7901, MKN-28, and MKN-45) using
qRT-PCR. As shown in Figure 2A, hsa-miR-134 was
highly expressed in SNU-5, AGS, HGC-27, MGC-803,
and MKN-28 cells but low in SNU-1 cells compared to
GES cells. In contrast, expression of hsa-miR-337-3p wasalignant gastric cell line GES and nine gastric cancer cell lines. A,
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HGC27, and SGC-7901, at a low level (Figure 2B).Effect of mimics and inhibitors of hsa-miR-134 and
hsa-miR-337-3p on MKN-45 cell proliferation
To determine the effects of hsa-miR-134 and hsa-miR-
337-3p on the regulation of gastric cancer growth and
invasion, we selected the MKN-45 cell line according to
its expression levels of these two miRNAs. The mimic
was used to determine whether overexpression of these
two miRNAs could inhibit tumor cell invasion in vitro,
whereas inhibitors were used as controls. (Although they
were downregulated in gastric tumor cells, they may
have certain levels of expression in tumor cells, and in-
hibition of their expression may also promote tumor cell
invasion.) We transfected hsa-miR-134 or hsa-miR-
337-3p mimics or inhibitors into MKN-45 cells and
performed a cell viability assay. The data revealed that
the changed expression of hsa-miR-134 or hsa-miR-
337-3p only slightly affected MKN-45 cell proliferation
(Figure 3). miRNA mimics and inhibitors used in this
study were listed in Additional file 3: Table S2.Figure 3 Time-course effects of miRNAs on the regulation of gastric can
MKN-45 cells. B, hsa-miR-134 inhibitor-transfected MKN-45 cells. Data are exprExpression of hsa-miR-337-3p affects MKN-45 cell
migration and invasion
Since these miRNAs were differentially expressed in pri-
mary and secondary gastric cancer tissues, we investigated
the effects of hsa-miR-134 and hsa-miR-337-3p on the
regulation of gastric cancer cell migration by transfecting
hsa-miR-134 and hsa-miR-337-3p mimics or inhibitors
into MKN-45 cells and then measured the tumor cell mi-
gration capacity. Next, the capacity of the transfected cells
was examined using a Transwell-Matrigel invasion assay.
Our data showed that transfection with the hsa-miR-134
mimic or inhibitor in MKN-45 cells did not affect the
tumor cell invasion capacity (Figure 4A; P>0.05). In con-
trast, the hsa-miR-337-3p mimic significantly decreased
the number of invaded cells (Figure 4B; P<0.05), indicating
that hsa-miR-337-3p overexpression may decrease the in-
vasive ability of gastric cancer cells.
Discussion
In this study, we profiled the differentially expressed
miRNAs between samples of gastric cancer and the cor-
responding metastatic lymph node gastric cancer tissues
using miRNA arrays. We found several miRNAs thatcer MKN-45 cell proliferation. A, hsa-miR-337-3p mimic-transfected
essed as mean ± SD; n=4.
Figure 4 The effect of hsa-miR-337-3p or hsa-miR-134 mimics
or inhibitors on the regulation of gastric cancer cell invasive
capacity. A, The migrated cell number of the hsa-miR-134 inhibitor-
transfected MNK-45 cells; B: The migrated cell number of the hsa-miR-
337-3p mimic-transfected MNK-45 cells. Data are expressed as mean ±
SD; n=4; *P<0.05, as compared to the control oligonucleotide (NC)
treated group.
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samples. Among them, we chose five of the most altered
miRNAs to be verified in paired primary and secondary
gastric cancers from 16 patients. Next, hsa-miR-134 and
hsa-miR-337-3p were transiently transfected into gastric
cancer cell lines, and the data showed that they only
slightly affected gastric cancer cell growth. However,
hsa-miR-337-3p overexpression reduced the invasive
ability of gastric cancer cells in vitro. Therefore, further
studies of the mechanism of hsa-miR-337-3p in gastric
cancer are warranted.
Although there are a number of published studies that
have investigated aberrant miRNA expression in cancer
development and progression in vitro and in vivo, little
research has focused on the altered expression of miRNAs
with cancer metastasis [16]. In the present study, we first
profiled the altered expression of miRNAs in metastatic
lymph node gastric cancer tissues by comparing them
with the corresponding primary tumor tissues. We found
that more than 400 miRNAs were differentially expressed
between these two types of gastric tissues. To date, therehave been several studies that have analyzed miRNA ex-
pression for its association with gastric cancer or metasta-
sis [8,14-19], and numerous altered miRNA expressions
have been reported [14-19], which was confirmed in our
current study. However, there have been no reports de-
scribing altered miRNA expression between primary gas-
tric cancer tissue and the corresponding metastatic lymph
node gastric cancer tissue. Our data support that altered
expression of miRNAs does play a role in tumor metasta-
sis. Further studies of these miRNA-targeted genes may
provide insightful information for us to understand the
molecular mechanisms of tumor metastasis.
Next, we verified 5 miRNAs from the miRNA profiling
data in 16 paired gastric cancer tissue samples and in 9
gastric cancer cell lines and found that these miRNA
levels were differentially expressed in the tissues and cell
lines. Among these five confirmed differentially expressed
miRNAs, only miR-483-5p had been previously reported
to be associated with human cancer development. For ex-
ample, Patterson et al. showed that altered expression of
miR-483-5p is associated with malignant pheochromocy-
toma after analyzing miRNA expression in benign and
malignant pheochromocytoma tumor samples [18]. Using
microarray analysis, qPCR confirmation, and Kaplan-
Meier analysis, upregulation of miR-483-5p was found
to be significant between adrenocortical carcinomas
and adrenocortical adenomas [19]. Although our current
data are preliminary, this study provides useful informa-
tion for future studies of miRNAs for their association
with gastric cancer metastasis.
Furthermore, our in vitro data showed that overexpression
of hsa-miR-337-3p in gastric tumor cells reduced tumor cell
invasive capacity but only slightly reduced gastric cancer cell
proliferation. However, to date, the underlying mechanism
for the association of hsa-miR-337-3p with human gastric
cancer metastasis is unknown. The hsa-miR-337-3p
(miR-337) gene is localized at chromosome 14q32.2. In
this chromosome locus, BCL11B may act as a tumor-
suppressor gene in T-cell acute lymphoblastic leukemia
[20,21]. However, the relationship between hsa-miR-337-3p
and BCL11B and their role in gastric cancer metastasis
needs to be further determined. Only a few studies
have described the role of hsa-miR-337-3p in human
tumorigenesis. For example, a previous study has shown
that hsa-miR-337-3p is highly expressed in immortalized
fetal lung fibroblast IMR-90 cells and is detectable in im-
mortalized human bronchial epithelial HBEC cells [22].
Another study has demonstrated that hsa-miR-337-3p is a
modulator of cellular response to taxanes [22]. Further-
more, hsa-miR-337-3p was able to regulate the expression
of STAT3 and RAP1A to mediate paclitaxel sensitivity
[22]. Indeed, constitutive STAT3 activation is associated
with various human cancers and commonly suggests poor
prognosis [23,24]. Previous studies have shown that
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tion of lymphocytes. Moreover, Rap GTPases are mas-
ter regulators of integrin activation, cell motility, and
the underlying cytoskeletal, adhesion, and membrane
dynamics. Rap activation is critical for B-lymphoma
cells to undergo transendothelial migration in vitro and
in vivo [25]. In addition, altered expression of hsa-miR-
337-3p may be critical in renal cell carcinoma (RCC) de-
velopment, although the analysis of circulating serum
levels of hsa-miR-337-3p is unlikely to provide helpful
diagnostic/prognostic information in RCC [26]. However,
a previous study has reported that hsa-miR-337-3p is
among 24 miRNAs that are significantly upregulated in
gastric cancer compared to normal gastric mucosae
[27], but that study did not specify how many cases
were used in the miRNA array analysis and did not
verify their results by qRT-PCR [16]. Thus, besides the
technological reasons, the previous contradiction of hsa-
miR-337-3p expression in gastric cancer can be explained
by their different metastatic potentials accordingly to our
current findings. Our current study demonstrated that
hsa-miR-337-3p acted as a potential therapeutic agent for
gastric cancer. For example, we may use a modified
hsa-miR-337-3p oligonucleotide mimic to function as
hsa-miR-337-3p to inhibit gastric cancer progression
and metastasis.
Conclusions
Our current study demonstrated hsa-miR-337-3p downregulation
in metastatic gastric cancer tissues and gastric cancer cell
lines. Our in vitro study showed that restored hsa-miR-
337-3p expression suppressed gastric cancer cell invasion,
suggesting that hsa-miR-337-3p may be a potential thera-
peutic agent to inhibit gastric cancer metastasis.
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